The multikinase inhibitor sorafenib, which has been approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, has emerged in the last years as a promising agent for treating tumors in which oncogenic kinases are frequently deregulated. 2 Recent studies have shown that CLL cells might be also susceptible to this compound. 3, 4 Thus, sorafenib could be particularly relevant in CLL cells by blocking RAF-mediated survival responses in the presence of CXCL12, 4 its cytotoxic effect being related to the translational inhibition of the antiapoptotic protein MCL-1. 3 In this context, the aim of our study was to investigate the capacity of sorafenib to interfere with B-cell receptor (BCR) signaling and to evaluate its efficacy in modulating migratory and microenvironmental prosurvival signals.
Peripheral blood (PB), BM or lymph node (LN) samples from CLL patients (n ¼ 45) were incubated with sorafenib at doses ranging from 2.5 to 15 mM. The biological characteristics of CLL patients are listed in Supplementary Table 1. In agreement with previous reports, 3, 4 we confirmed that sorafenib induced a dose-dependent apoptosis in all CLL samples, including those bearing adverse cytogenetic alterations, with a mean lethal dose 50 of 9.71 ± 2.14 mM at 24 h (Supplementary Table 1 and Supplementary Figure 1A ). The unmutated IGHV group was significantly more sensitive than the mutated IGHV group (*P ¼ 0.01; Supplementary Figure 1B) . Importantly, as shown in Figure 1a , the sensitivity to sorafenib of PB mononuclear cells from healthy donors was significantly lower when compared with CLL cells (***Po0.001), both in T lymphocytes (CD3 þ cells) and B lymphocytes (CD19 þ cells). Thus, these results demonstrate that the cytotoxic effect of sorafenib is selective for tumoral lymphocytes, at least in the range of doses achievable in vivo.
5 Noteworthy, we compared the sensitivity to sorafenib of CLL cells obtained simultaneously from the three compartments, PB, LN and BM, and as shown in Figure 1b , sorafenib was significantly more cytotoxic in CD19 þ lymphocytes isolated from LN than those from PB or BM (***Po0.001 at 7.5 mM; **Po0.01 at 10 mM).
As previously reported, 3 we confirmed that sorafenib induced a downregulation of MCL-1 in CLL cells, due to the translational inhibition of this antiapoptotic protein (Supplementary Figure 2A) . However, the basal levels of MCL-1 did not correlate with sorafenib cytotoxicity (data not shown), indicating that other factors may be underlying the effect of this compound in CLL cells. We also found that extracellular-signal-regulated kinase (ERK) inhibition by sorafenib in CLL cells was an early, but not sustained event; thus, downregulation of RAF/MEK/ERK pathway was not a crucial effect of this agent in CLL (Supplementary Figure 2B) . Given the role of the BCR in CLL pathogenesis, we focused our study on the effect of sorafenib on BCR kinases, in particular the SRC family and the spleen tyrosine kinase (SYK), which are overexpressed and activated in CLL. 6 --8 To assess this, surface IgM was cross-linked, (e) CLL cells were pretreated 2 h with sorafenib (7.5 and 10 mM) before adding fludarabine (1 mg/ml) or bendamustine (25 mM), with or without stroma. Viability at 48 h was calculated relative to the respective untreated control, with or without the stroma. Mean ± s.e.m. of six representative cases. Fludar., fludarabine; Bendam., bendamustine; Soraf., sorafenib.
Letters to the Editor and proximal and distal events were analyzed. As shown in Figure 1c (left panel), sorafenib overcame BCR stimulation and induced apoptosis with the same efficiency in IgM-stimulated CLL cells (**P ¼ 0.006) as in non-stimulated cells (**P ¼ 0.002). At the molecular level, sorafenib simultaneously inhibited the phosphorylation of SYK and SRC after BCR engagement, as well as its downstream signaling events (Figure 1c , right panel). This effect was more pronounced in unmutated IGHV cells (CLL13; Figure 1c , right panel), which respond better to IgM stimulation. 9 In line with this hypothesis, our results showing a higher cytotoxic effect of sorafenib in unmutated CLL cells indicate that this compound could be particularly effective in high-risk CLL patients.
To further confirm the functional value of these findings, we evaluated whether sorafenib could block T-cell attracting chemokines CCL3 and CCL4 secretion by CLL cells in response to BCR stimulation. As shown in Figure 1d , BCR stimulation increased CCL3 and CCL4 mRNA levels, whereas preincubation with sorafenib significantly blocked this induction (CCL3: **P ¼ 0.003; CCL4: **P ¼ 0.01). All these results support the hypothesis that sorafenib is able to block BCR-derived survival responses in CLL cells.
There is growing evidence that the stromal microenvironment may protect CLL cells from spontaneous and drug-induced apoptosis. 10 In this context, we analyzed the effect of sorafenib in the coculture of CLL cells with the BM-derived stromal cell line HS-5. We confirmed that the stroma protected CLL cells from spontaneous apoptosis, but not from sorafenib-induced apoptosis (Supplementary Figure 3A) . Moreover, western blot analysis showed that sorafenib efficiently inhibited the phosphorylation of SYK, SRC and ERK induced by the contact with HS-5 (Supplementary Figure 3B) .
We also compared the ability of sorafenib to synergize with fludarabine and bendamustine, both of them used in CLL treatment. CLL samples, with and without the stroma, were pretreated 2 h with sorafenib before fludarabine or bendamustine addition, and viability was assessed at 48 h. In the absence of stroma, no additive or synergistic effect between the combination of both fludarabine and bendamustine with sorafenib was observed (Figure 1e) , consistent with the results previously reported. 3 As expected, the presence of HS-5 reverted significantly fludarabine and bendamustine cytotoxicities (fludarabine: ***Po0.0001; bendamustine: ***P ¼ 0.0009). Importantly, sorafenib prevented this protective effect in a dose-dependent manner, so that the relative viability of CLL cells exposed to 7.5 mM sorafenib in combination with either fludarabine or bendamustine resulted in no significant changes with or without stroma. When these drugs were combined with sorafenib at 10 mM, the apoptosis induction became significantly more potent with than without HS-5 coculture (fludarabine: *P ¼ 0.0169; bendamustine: *P ¼ 0.0443; Figure 1e ). Altogether, these data suggest that sorafenib could overcome stroma-mediated chemoresistance in CLL.
Targets downstream of SRC activation include focal adhesion kinase (FAK), which promotes invasiveness and may act to link BCR signaling and migration/adhesion via effects on the cytoskeleton. 11 Therefore, we evaluated the effects of sorafenib on the migratory capacity of CLL cells, using the chemotaxis assay described in Materials and Methods (Supplementary Information). Sorafenib reduced significantly CLL cell migration in the presence of the chemokine CXCL12 (Figure 2a ; ***P ¼ 0.0003). This effect was not observed when CLL cells were incubated with fludarabine 1 mg/ml, used as a negative control. Importantly, the inhibitory effect of sorafenib was highly significant in CLL cells derived from LN and BM samples (BM: *P ¼ 0.012; LN: **P ¼ 0.007; Figure 2b ). These results are in accordance with the observation that sorafenib is more effective in LN-derived CLL cells compared with the PB counterpart. Thus, sorafenib may target CLL cells in their protected LN niche, where BCR and other survival pathways are more activated, 12 and that are often responsible for disease relapses. 10 In parallel, we analyzed the effect of sorafenib on the phosphorylation status of CXCL12-stimulated kinases by western blot. As displayed in Figure 2c , sorafenib almost completely abrogated the CXCL12-induced activation of the downstream SRCtarget FAK. To further define the functional link between SRC and FAK, CLL cells stimulated with anti-IgM were assessed for migration toward CXCL12 as above. As shown in Figure 2d , the inhibitory effect of sorafenib in blocking migration was highly significant in BCR-stimulated cells (***Po0.0001). Accordingly, BCR stimulation of CLL cells induced an increase on FAK phosphorylation that was almost completely reverted by sorafenib (Figure 2d , right panel). Our results provide evidence for the first time that FAK is activated in response to BCR stimulation in CLL cells, thus indicating that this kinase can have a role in modulating CLL migration. In summary, sorafenib inhibits migration, antagonizes both CXCL12-and BCR-induced FAK activation, and could be particularly effective in CLL cells with high migratory potential.
Collectively, our results provide a novel mechanism of action of the multikinase inhibitor sorafenib in CLL cells, establishing that this compound could overcome the protective effect of the CLL microenvironment at different levels, such as prosurvival signaling, chemokine production and migration, by abrogating BCR-derived responses.
